Top

Published in:

01-02-2010 | Preclinical Study

Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer

Authors: De-Yuan Fu, Zhi-Min Wang, Li-Chen, Bei-Lan Wang, Zhen-Zhou Shen, Wei Huang, Zhi-Ming Shao

Published in: Breast Cancer Research and Treatment | Issue 3/2010

Abstract

SRY-box 17 (Sox17) is a transcription factor which involved in a variety of developmental processes and can act as an antagonist of canonical Wnt/β-catenin signaling pathway. However, the relationship between Sox17 gene expression, methylation status, and β-catenin in breast cancer has not been established. Here we report that the expression level of Sox17 mRNA was dramatically decreased in five different breast cancer cell lines and 23 of 31 primary breast tumor samples, which significantly correlated with its methylation status. After treated with 5-aza-2′-deoxycytidine (5-aza-dC, a demethylation agent), the expression levels of Sox17 mRNA and protein were obviously increased. Restored expression of Sox17 by 5-aza-dC treatment decreased the expression level of β-catenin in breast cancer cell lines. Furthermore, small interfering RNA (siRNA)-mediated knockdown of Sox17 in SKBR-3 and Bacp-37 cells enhanced β-catenin expression. In 31 paired tissue samples, a significant difference between the expression level of Sox17 and β-catenin was also observed (P < 0.001). Clinically, Sox17 methylation was detected in 74.3% breast tumors (84/113) and 31.9% (36/113) paired normal tissues, respectively (P < 0.0001). Sox17 methylation was also associated with tumor stage (P = 0.028) and lymph node metastasis (P = 0.013). These findings indicate that silencing of Sox17 due to promoter hypermethylation is a frequent event and may contribute to aberrant activation of Wnt signaling in breast cancer. Sox17 may be a valuable biomarker for the study of breast cancer carcinogenesis and progression.

Jemal A, Siegel R, Ward E et al (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43–66CrossRefPubMed

Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042–2054. doi:10.1056/NEJMra023075 CrossRefPubMed

Das PM, Singal R (2007) DNA methylation and cancer. J Clin Oncol 22:4632–4642. doi:10.1200/JCO.2004.07.151 CrossRef

Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128:683–692. doi:10.1016/j.cell.2007.01.029 CrossRefPubMed

Szyf M, Pakneshan P, Rabbani SA (2004) DNA methylation and breast cancer. Biochem Pharmacol 68:1187–1197. doi:10.1016/j.bcp.2004.04.030 CrossRefPubMed

Agrawal A, Murphy RF, Agrawal DK (2007) DNA methylation in breast and colorectal cancers. Mod Pathol 20:711–721. doi:10.1038/modpathol.3800822 CrossRefPubMed

Kamachi Y, Uchikawa M, Kondoh H (2000) Pairing SOX off: with partners in the regulation of embryonic development. Trends Genet 16:182–187. doi:10.1016/S0168-9525(99)01955-1 CrossRefPubMed

Wegner M (1999) From head to toes: the multiple facets of Sox proteins. Nucleic Acids Res 27:1409–1420. doi:10.1093/nar/27.6.1409 CrossRefPubMed

Kiefer JC (2007) Back to basics: Sox genes. Dev Dyn 236:2356–2366. doi:10.1002/dvdy.21218 CrossRefPubMed

10.

Lefebvre V, Dumitriu B, Penzo-Méndez A et al (2007) Control of cell fate and differentiation by Sry-related high-mobility-group box (Sox) transcription factors. Int J Biochem Cell Biol 39:2195–2214. doi:10.1016/j.biocel.2007.05.019 CrossRefPubMed

11.

Dong C, Wilhelm D, Koopman P (2004) Sox genes and cancer. Cytogenet Genome Res 105:442–447. doi:10.1159/000078217 CrossRefPubMed

12.

Sohn J, Natale J, Chew LJ, Belachew S et al (2006) Identification of Sox17 as a transcription factor that regulates oligodendrocyte development. J Neurosci 26:9722–9735. doi:10.1523/JNEUROSCI.1716-06.2006 CrossRefPubMed

13.

Matsui T, Kanai-Azuma M, Hara K et al (2006) Redundant roles of Sox17 and Sox18 in postnatal angiogenesis in mice. J Cell Sci 119:3513–3526. doi:10.1242/jcs.03081 CrossRefPubMed

14.

Park KS, Wells JM, Zorn AM et al (2006) Sox17 influences the differentiation of respiratory epithelial cells. Dev Biol 294:192–202. doi:10.1016/j.ydbio.2006.02.038 CrossRefPubMed

15.

Shimoda M, Kanai-Azuma M, Hara K et al (2007) Sox17 plays a substantial role in late-stage differentiation of the extraembryonic endoderm in vitro. J Cell Sci 120:3859–3869. doi:10.1242/jcs.007856 CrossRefPubMed

16.

Kim I, Saunders TL, Morrison SJ (2007) Sox17 dependence distinguishes the transcriptional regulation of fetal from adult hematopoietic stem cells. Cell 130:470–483. doi:10.1016/j.cell.2007.06.011 CrossRefPubMed

17.

Jang YY, Sharkis SJ (2007) Fetal to adult stem cell transition: knocking Sox17 off. Cell 130:403–404. doi:10.1016/j.cell.2007.07.027 CrossRefPubMed

18.

Liu Y, Asakura M, Inoue H et al (2007) Sox17 is essential for the specification of cardiac mesoderm in embryonic stem cells. Proc Natl Acad Sci USA 104:3859–3864. doi:10.1073/pnas.0609100104 CrossRefPubMed

19.

Sinner D, Kordich JJ, Spence JR et al (2007) Sox17 and Sox4 differentially regulate beta-catenin/T-cell factor activity and proliferation of colon carcinoma cells. Mol Cell Biol 27:7802–7815. doi:10.1128/MCB.02179-06 CrossRefPubMed

20.

Zhang W, Glöckner SC, Guo M et al (2008) Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res 68:2764–2772. doi:10.1158/0008-5472.CAN-07-6349 CrossRefPubMed

21.

Zorn AM, Barish GD, Williams BO et al (1999) Regulation of Wnt signaling by Sox proteins: XSox17 alpha/beta and XSox3 physically interact with beta-catenin. Mol Cell 4:487–498. doi:10.1016/S1097-2765(00)80200-2 CrossRefPubMed

22.

Kanai-Azuma M, Kanai Y, Gad JM et al (2002) Depletion of definitive gut endoderm in Sox17-null mutant mice. Development 129:2367–2379PubMed

23.

de Jong J, Stoop H, Gillis AJ et al (2008) Differential expression of Sox17 and SOX2 in germ cells and stem cells has biological and clinical implications. J Pathol 215:21–30. doi:10.1002/path.2332 CrossRefPubMed

24.

Morin PJ, Weeraratna AT (2003) Wnt signaling in human cancer. Cancer Treat Res 115:169–187. doi:10.1007/0-306-48158-8_7 CrossRefPubMed

25.

Karim R, Tse G, Putti T et al (2004) The significance of the Wnt pathway in the pathology of human cancers. Pathology 36:120–128. doi:10.1080/00313020410001671957 CrossRefPubMed

26.

Brantjes H, Barker N, van Es J et al (2002) Lady justice casting the final verdict on the outcome of Wnt signalling. Biol Chem 383:255–261. doi:10.1515/BC.2002.027 CrossRefPubMed

27.

Li Y, Welm B, Podsypanina K et al (2003) Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci USA 100:15853–15858. doi:10.1073/pnas.2136825100 CrossRefPubMed

28.

Howe LR, Brown AM (2004) Wnt signaling and breast cancer. Cancer Biol Ther 3:36–41PubMed

29.

Veeck J, Niederacher D, An H et al (2006) Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene 25:3479–3488. doi:10.1038/sj.onc.1209386 CrossRefPubMed

30.

Lo PK, Mehrotra J, D’Costa A et al (2006) Epigenetic suppression of secreted frizzled related protein 1 (SFRP1) expression in human breast cancer. Cancer Biol Ther 5:281–286PubMedCrossRef

31.

Veeck J, Geisler C, Noetzel E et al (2008) Epigenetic inactivation of the secreted frizzled-related protein-5 (SFRP5) gene in human breast cancer is associated with unfavorable prognosis. Carcinogenesis 29:991–998. doi:10.1093/carcin/bgn076 CrossRefPubMed

32.

Ai L, Tao Q, Zhong S et al (2006) Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. Carcinogenesis 27:1341–1348. doi:10.1093/carcin/bgi379 CrossRefPubMed

33.

Suzuki H, Toyota M, Carraway H et al (2008) Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. Br J Cancer 98:1147–1156. doi:10.1038/sj.bjc.6604259 CrossRefPubMed

34.

Akiyama H, Lyons JP, Mori-Akiyama Y et al (2004) Interactions between Sox9 and beta-catenin control chondrocyte differentiation. Genes Dev 18:1072–1087. doi:10.1101/gad.1171104 CrossRefPubMed

35.

Takash W, Cañizares J, Bonneaud N et al (2001) SOX7 transcription factor: sequence, chromosomal localisation, expression, transactivation and interference with Wnt signalling. Nucleic Acids Res 29:4274–4283. doi:10.1093/nar/29.21.4274 CrossRefPubMed

36.

Sinner D, Rankin S, Lee M et al (2004) Sox17 and beta-catenin cooperate to regulate the transcription of endodermal genes. Development 131:3069–3080. doi:10.1242/dev.01176 CrossRefPubMed

37.

Katoh M (2002) Molecular cloning and characterization of human Sox17. Int J Mol Med 9:153–157PubMed

38.

Feltus FA, Lee EK, Costello JF et al (2004) Predicting aberrant CpG island methylation. Proc Natl Acad Sci USA 100:12253–12258. doi:10.1073/pnas.2037852100 CrossRef

39.

Ushijima T (2005) Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 5:23–31. doi:10.1038/nrc1571 CrossRef

40.

Kimelman D, Xu W (2006) Beta-catenin destruction complex: insights and questions from a structural perspective. Oncogene 25:7482–7491. doi:10.1038/sj.onc.1210055 CrossRefPubMed

41.

Lin SY, Xia W, Wang JC et al (2000) Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA 97:4262–4266. doi:10.1073/pnas.060025397 CrossRefPubMed

42.

Turashvili G, Bouchal J, Burkadze G et al (2006) Wnt signaling pathway in mammary gland development and carcinogenesis. Pathobiology 73:213–223. doi:10.1159/000098207 CrossRefPubMed

43.

Dolled-Filhart M, McCabe A, Giltnane J et al (2006) Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res 66:5487–5494. doi:10.1158/0008-5472.CAN-06-0100 CrossRefPubMed

44.

Candidus S, Bischoff P, Becker KF et al (1996) No evidence for mutations in the alpha- and beta-catenin genes in human gastric and breast carcinomas. Cancer Res 56:49–52PubMed

45.

Kawano Y, Kypta R (2003) Secreted antagonists of the Wnt signalling pathway. J Cell Sci 116:2627–2634. doi:10.1242/jcs.00623 CrossRefPubMed

Title: Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer
Authors: De-Yuan Fu
Zhi-Min Wang
Li-Chen
Bei-Lan Wang
Zhen-Zhou Shen
Wei Huang
Zhi-Ming Shao
Publication date: 01-02-2010
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-009-0339-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2010

NIP1/DUOXA1 expression in epithelial breast cancer cells: regulation of cell adhesion and actin dynamics

Women’s decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid

Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer

Characterization of BRCA1 ring finger variants of uncertain significance

Dietary β-carotene, vitamin C and E intake and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC)

A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (≤1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer